Panelists:
Manu Verma, PhD
Senior Research Scientist
Functional Genomics Novo Nordisk Research Center Oxford
Andy Conery, PhD
Executive Director Biology and Translational Sciences TRIANA Biomedicines
John Feder, PhD
Scientific Director Cell and Genome Engineering
Bristol Myers Squibb
Michelle Fraser
Head, Cell and Gene Therapy Business Unit
Revvity
- Time:
Gene editing technology is being widely deployed to generate precise data about disease-causing gene mutations and networks, helping to identify optimal therapeutic targets. These approaches are fueling efforts to develop cell and gene therapies for a growing number of genetic disorders among an estimated 6,000 Mendelian diseases, most of which still lack cures.
In this GEN webinar, our expert panelists will discuss recent insights into the relationship between human genetic variation and disease from functional genomic studies. They will share their preferred strategies for improving payload development and delivery in functional genomics studies using gene editing.
Key takeaways include:
· An understanding of the complexities of therapeutic development including cell and gene engineering and manufacturing challenges.
· An introduction to Revvity’s Dharmacon product suite—solutions for targeted editing in almost any cell type including CRISPR knockout, knock-in, and interference.
Produced with support from:
